Phase I SC-CAR.GPC3xIL15.21 pediatric/AYA CAR-T for GPC3+ non-CNS solid tumors (incl. HCC)

Seattle Children’s runs a first-in-human, single-infusion CAR-T armed with IL-15/21 plus an inducible safety switch for GPC3-positive tumors. Pediatric/AYA liver and other GPC3+ cancers (neuroblastoma) have sparse targeted options; enhanced persistence signals from IL-15/21 could be decisive. Safety, feasibility, and early antitumor activity will steer expansion into specific histologies.